Abp 692

Phase 3

Abp 692 is one of 2 therapeutic programs targeting Relapsing Remitting Multiple Sclerosis (RRMS). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Relapsing Remitting Multiple Sclerosis (RRMS)Active, not recruiting

Relapsing Remitting Multiple Sclerosis (RRMS)Phase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Relapsing Remitting Multiple Sclerosis (RRMS)

#DrugCompanyPhaseTrials

Rocbrutinib

GGuangzhou Lupeng Pharmaceutical Company LTD.

Phase 2

1 2

Abp 692

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Relapsing Remitting Multiple Sclerosis (RRMS)

NCT06700343

Clinical

Trials by Indication[1]

Relapsing Remitting Multiple Sclerosis (RRMS)1 trial

A Randomized, Double-blind Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics, and Clinical Effects Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis

Active, not recruiting· Amgen logo

Amgen·Phase 3·NCT06700343·152 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Abp 692. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Abp 692. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Amgen

Abp 692

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Relapsing Remitting Multiple Sclerosis (RRMS)1 trial

References

Drug Info

Quick Facts

Related News